Flucloxacilina Noridem

Flucloxacilina Noridem is a prescription injectable medication that contains the beta‑lactam antibiotic flucloxacillin. It is supplied as a solution for intramuscular or intravenous administration and is marketed in the European Union. The product is indicated for a range of skin, bone, joint and respiratory tract infections where susceptible organisms are identified.

Flucloxacilina Noridem is indicated for infections that are known or suspected to be caused by penicillin‑ase‑producing Gram‑positive bacteria, especially Staphylococcus aureus.

- Skin and soft tissue infections such as cellulitis, impetigo, and wound infections. - Bone and joint infections including osteomyelitis and septic arthritis. - Respiratory tract infections like community‑acquired pneumonia caused by susceptible strains. - Staphylococcal infections of the bloodstream or prosthetic devices. - Surgical prophylaxis where penicillin‑resistant staphylococci are a concern.

Adverse reactions to flucloxacillin are generally mild and reversible, but serious events can occur and should be promptly recognized and managed.

Common: - Diarrhea or loose stools. - Nausea and occasional vomiting. - Skin rash or mild itching. - Elevated liver enzymes without symptoms. - Headache or dizziness. - Metallic taste in the mouth.

Serious: - Severe allergic reactions such as anaphylaxis or angioedema. - Hepatotoxicity presenting as jaundice, hepatitis, or cholestasis. - Blood disorders including neutropenia or thrombocytopenia. - Acute interstitial nephritis leading to renal impairment. - Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Flucloxacilina Noridem, clinicians should evaluate patient history and laboratory results to minimize risk of adverse outcomes.

- Assess liver function; flucloxacillin may cause cholestatic hepatitis, especially with prolonged therapy. - Review renal function; dose adjustment may be needed in severe impairment. - Obtain a detailed allergy history, particularly prior reactions to penicillins or cephalosporins. - Use caution in patients with a history of jaundice, hepatitis, or biliary disease. - Avoid use in newborns and premature infants due to limited safety data. - Monitor complete blood count during long‑term treatment for possible neutropenia or thrombocytopenia. - Consider alternative agents in patients receiving oral contraceptives, as flucloxacillin can reduce efficacy.

Flucloxacilina Noridem can alter the pharmacokinetics of several drugs; awareness of these interactions helps prevent therapeutic failure or toxicity.

Avoid: - Oral contraceptives containing estrogen or progestin, as flucloxacillin may increase hormone metabolism and reduce contraceptive effectiveness. - Methotrexate, because flucloxacillin can decrease renal clearance and raise methotrexate levels, raising toxicity risk. - Warfarin, where flucloxacillin may potentiate anticoagulant effect and increase INR.

Use with caution: - Antacids or proton pump inhibitors that contain aluminum or magnesium, which may reduce flucloxacillin absorption if given orally. - Rifampicin, a potent enzyme inducer that can lower flucloxacillin concentrations. - Cyclosporine, as flucloxacillin may increase cyclosporine levels and require monitoring.